Photo: Depositphotos
Jul 14, 2025, 18:03
One of the Most Promising Areas in Lung Cancer Research and Things Are Moving Fast – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn:
“What even is an ADC?
You’ve probably heard the term, especially if you’re following new treatment developments in lung cancer. But what does it actually mean?
ADCs (antibody-drug conjugates) are a type of targeted therapy that link an antibody to a chemotherapy drug. The idea? Deliver chemo directly to the tumour, with less damage to healthy cells.
They’re already used in some lung cancers like HER2+ and EGFR Exon20 and more are in trials. Researchers are now finding new ways to match ADCs to different tumours using RNA, protein, and even ctDNA.
It’s one of the most promising areas in lung cancer research and things are moving fast.”
More posts featuring Lung Cancer Europe on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 14, 2025, 17:58
Jul 14, 2025, 17:51
Jul 14, 2025, 17:47
Jul 14, 2025, 17:35
Jul 14, 2025, 16:49
Jul 14, 2025, 16:38